Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 348 · FY2023 4,587 · FY2024 5,117 — 3-yr total 10,052
Georgian pharmaceutical retail / wholesale company. Limited public information available beyond the Reportal filing.
Group parent — controls 1 company · ownership
| Ratio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||
| Gross Margin | 11.6% | 24.1% | 19.4% | 11.5% | 11.6% | 7.1% | 24.7% | 22.7% |
| EBITDA Margin | 9.7% | 17.7% | -181.8% | 2.6% | 5.0% | 1.0% | 18.4% | 16.4% |
| EBITDAR | 5,384 | 10,720 | -110,721 | 1,555 | 3,714 | 753 | 13,017 | 12,124 |
| EBITDAR Margin | 9.7% | 17.7% | -181.8% | 2.6% | 5.0% | 1.0% | 18.4% | 16.4% |
| EBIT Margin | 8.6% | 16.4% | -184.1% | -1.6% | 3.3% | -1.0% | 16.9% | 15.1% |
| Net Profit Margin | 6.3% | 22.4% | 21.8% | -17.8% | 8.8% | 13.4% | 13.1% | 7.2% |
| Operating Expense % of Sales | 1.9% | 6.4% | 223.2% | 9.0% | 6.6% | 6.0% | 6.3% | 6.4% |
| Returns | ||||||||
| Return on Assets (ROA) | 5.0% | 16.3% | 13.1% | -9.6% | 5.3% | 7.1% | 6.1% | 2.8% |
| Return on Equity (ROE) | N/A | 76.8% | 45.5% | -56.3% | 24.4% | 29.5% | 24.9% | 14.1% |
| ROIC [EBIT / Invested Capital] | 67.2% | 37.8% | -248.0% | -2.5% | 5.2% | -1.4% | 20.7% | 17.3% |
| Leverage & debt balances | ||||||||
| Debt-to-Assets | 13.8% | 14.1% | 17.1% | 18.0% | 20.2% | 17.3% | 16.4% | 17.9% |
| Debt-to-Equity | -36.24x | 0.66x | 0.60x | 1.05x | 0.94x | 0.72x | 0.67x | 0.90x |
| Debt-to-EBITDA | 1.78x | 1.10x | N/A | 12.98x | 6.80x | 31.07x | 1.93x | 2.78x |
| Equity-to-Assets | -0.4% | 21.2% | 28.8% | 17.1% | 21.6% | 24.1% | 24.5% | 19.9% |
| Net Debt | 7,345 | 8,626 | 16,016 | 18,883 | 20,228 | 20,408 | 20,334 | 27,026 |
| Cash & Equivalents | 2,258 | 3,152 | 1,359 | 1,310 | 5,032 | 2,993 | 4,741 | 6,673 |
| Total Debt | 9,603 | 11,778 | 17,374 | 20,194 | 25,260 | 23,402 | 25,075 | 33,699 |
| Liquidity & working capital | ||||||||
| Current Ratio | 0.77x | 0.87x | 0.82x | 0.75x | 0.82x | 0.87x | 0.85x | 0.93x |
| Quick Ratio | 0.24x | 0.32x | 0.26x | 0.24x | 0.37x | 0.33x | 0.28x | 0.28x |
| Cash Ratio | 0.04x | 0.05x | 0.02x | 0.01x | 0.06x | 0.03x | 0.05x | 0.05x |
| Total Current Assets | 46,831 | 56,012 | 56,900 | 67,022 | 70,572 | 75,696 | 86,433 | 116,622 |
| Total Current Liabilities | 60,780 | 64,601 | 69,478 | 89,940 | 86,437 | 87,245 | 101,096 | 125,430 |
| Inventory | 32,376 | 35,165 | 38,972 | 45,702 | 38,445 | 46,823 | 57,848 | 81,702 |
| Trade Receivables | 11,003 | 11,618 | 13,653 | 18,640 | 24,725 | 25,116 | 23,439 | 27,638 |
| Trade Payables | 52,617 | 52,631 | 53,968 | 72,292 | 71,916 | 79,290 | 90,142 | 116,111 |
| Net Working Capital | -13,949 | -8,589 | -12,579 | -22,918 | -15,865 | -11,549 | -14,663 | -8,809 |
| Net Working Capital % of Revenue | -25.2% | -14.2% | -20.6% | -37.8% | -21.2% | -16.0% | -20.8% | -11.9% |
| Trade Working Capital | -9,238 | -5,848 | -1,343 | -7,950 | -8,746 | -7,351 | -8,855 | -6,771 |
| Trade Working Capital % of Revenue | -16.7% | -9.6% | -2.2% | -13.1% | -11.7% | -10.2% | -12.5% | -9.1% |
| Change in Trade Working Capital | N/A | 3,390 | 4,505 | -6,608 | -796 | 1,396 | -1,504 | 2,083 |
| Turnover & efficiency | ||||||||
| Inventory Turnover | 1.51x | 1.31x | 1.26x | 1.17x | 1.72x | 1.43x | 0.92x | 0.70x |
| Days Inventory Outstanding (DIO) | 241.3 | 278.6 | 289.6 | 310.9 | 212.1 | 254.9 | 397.3 | 521.1 |
| Receivables Turnover | 5.04x | 5.22x | 4.46x | 3.25x | 3.03x | 2.87x | 3.01x | 2.68x |
| Days Sales Outstanding (DSO) | 72.5 | 69.9 | 81.8 | 112.2 | 120.6 | 127.1 | 121.2 | 136.2 |
| Payables Turnover | 0.93x | 0.88x | 0.91x | 0.74x | 0.92x | 0.85x | 0.59x | 0.49x |
| Days Payable Outstanding (DPO) | 392.2 | 417.0 | 401.1 | 491.8 | 396.8 | 431.6 | 619.1 | 740.5 |
| Cash Conversion Cycle | -78.4 days | -68.5 days | -29.6 days | -68.7 days | -64.1 days | -49.7 days | -100.6 days | -83.3 days |
| Asset Turnover | 0.79x | 0.73x | 0.60x | 0.54x | 0.60x | 0.53x | 0.46x | 0.39x |
| Cash flow & dividends | ||||||||
| Operating Cash Flow | 6,063 | 8,821 | 12,706 | 2,721 | 8,989 | 4,587 | 9,734 | 5,152 |
| Free Cash Flow (OCF − Capex proxy) | 6,063 | 1,823 | -4,268 | -906 | -2,814 | 1,557 | 4,551 | -676 |
| Cash Conversion (OCF / EBITDA) | 112.6% | 82.3% | N/A | 174.9% | 242.0% | 609.0% | 74.8% | 42.5% |
| Dividends Declared | 0 | 3,125 | 2,112 | 1,250 | 100 | 348 | 4,587 | 5,117 |
| Dividend Payout Ratio | 0.0% | 22.9% | 15.9% | N/A | 1.5% | 3.6% | 49.5% | 96.5% |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →